D.E. Shaw & Co
SGMO

D.E. Shaw & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

D.E. Shaw & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-63,600
Closed -$971K – 4357
2014
Q2 		$971K Hold
63,600
– – ﹤0.01% 2971
2014
Q1 		$1.15M Buy
+63,600
New +$1.23M ﹤0.01% 2895

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

D.E. Shaw & Co's SGMO Position: Q3 2024 in Review

D.E. Shaw & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 1,165,993 shares — an estimated $418K sold.

D.E. Shaw & Co first reported a position in SGMO in Q3 2013 and held it in 41 quarters. The position peaked at $24.1M in Q3 2017. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • D.E. Shaw & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,165,993 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $418K.
  • D.E. Shaw & Co first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 41 quarters.
  • D.E. Shaw & Co's SANGAMO THERAPEUTICS INC position peaked at $24.1M in Q3 2017.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.